Skip to main content
PMC home page
AAPS PharmSciTech logoLink to AAPS PharmSciTech
. 2004 Aug 20;5(4):153–159. doi: 10.1208/pt050471

Comparative in vitro and in vivo evaluation of matrix, osmotic matrix, and osmotic pump tablets for controlled delivery of diclofenac sodium

Meena Rani 1, Brahmeshwar Mishra 1
PMCID: PMC2750496  PMID: 15760068

Abstract

The aim of this investigation was preparation and comparative evaluation of fabricated matrix (FM), osmotic matrix (OM), and osmotic pump (OP) tablets for controlled delivery of diclofenac sodium (DS). All formulations were evaluated for various physical parameters, and in vitro studies were performed on USP 24 dissolution apparatus II in pH 7.4 buffer and distilled water. In vivo studies were performed in 6 healthy human volunteers; the drug was assayed in plasma using HPLC, and results were compared with the performance of 2 commercial tablets of DS. Various pharmacokinetic parameters (ie, Cmax, Tmax, area under the curve [AUC0–24], and mean residence time) and relative bioavailability were compared. All fabricated formulations showed more prolonged and controlled DS release compared with commercial tablets studied. The OM and OP tablets, however, performed better than the matrix tablets. The rate and extent of drug release from FM1 matrix tablets (single polymer) was significantly different from that of FM2 (admixed polymers). Type of porosigenic agents and osmogens also influenced the drug release. Analysis of in vitro data by regression coefficient analysis revealed zero-order release kinetics for OM and OP tablets, while FM tablets exhibited Higuchi kinetics. In vivo results indicated prolonged blood levels with delayed peak and improved bioavailability for fabricated tablets compared to commercial tablets. It was concluded that the osmotic matrix and osmotic pump tablets could provide more prolonged, controlled, and gastrointestinal environmental-independent DS release that may result in an improved therapeutic efficacy and patient compliance.

Keywords: Matrix tablets, osmotic matrix tablets, osmotic pump tablets, controlled release, diclofenac sodium

Full Text

The Full Text of this article is available as a PDF (842.6 KB).

Contributor Information

Meena Rani, Phone: +91 542-2307049, FAX: +91 542-2368428/2368160, Email: immeena@rediffmail.com.

Brahmeshwar Mishra, Phone: +91 542-2307049, FAX: +91 542-2368428/2368160, Email: bmishrabhu@rediffmail.com.

References

  • 1.Zuckner J. International experience with diclofenac in rheumatoid arthritis. Am J Med. 1986;80:39–42. doi: 10.1016/0002-9343(86)90078-1. [DOI] [PubMed] [Google Scholar]
  • 2.Shoutakis VA, Carter CA, Mickle TR, Smith VH, Arkin CR, Alissandros J, Petty DE. Review of diclofenac and evaluation of its place in therapy as a nonsteroidal antiinflammatory agent. Drug Intel Clin Pharm. 1988;22:850–859. doi: 10.1177/106002808802201102. [DOI] [PubMed] [Google Scholar]
  • 3.Torres D, Garcia-Encina G, Seijo B, Vila Jato JL. Formulation and invitro evaluation of HPMCP-microencapsulated drug-resin complexes for sustained release of diclofenac. Int J Pharm. 1995;121:239–243. doi: 10.1016/0378-5173(95)00020-J. [DOI] [Google Scholar]
  • 4.Nokhodchi A, Farid DJ, Najafi M, Adrangui M. Studies on controlled-release formulations of diclofenac sodium. Drug Dev Ind Pharm. 1997;23:1019–1023. [Google Scholar]
  • 5.Sajeev C, Vinay G, Archna R, Saha RN. Oral controlled release formulation of diclofenac sodium by microencapsulation with ethyl cellulose. J Microencapsul. 2002;19:753–760. doi: 10.1080/0265204021000022734. [DOI] [PubMed] [Google Scholar]
  • 6.Tiwari SB, Murthy TK, Pai MR, Mehta PR, Chowdary PB. Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix system. AAPS PharmSciTech. 2003;4:E31–E31. doi: 10.1208/pt040331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Salsa T, Veiga F, Pina ME. Oral controlled-release dosage forms. I. Cellulose ether polymers in hydrophilic matrices. Drug Dev Ind Pharm. 1997;23:929–938. doi: 10.3109/03639049709148697. [DOI] [PubMed] [Google Scholar]
  • 8.Efentakis M, Koutlis A, Vlachou M. Development and evaluation of oral multiple-unit and single-unit hydrophilic controlled release systems. AAPS PharmSciTech. 2000;1:E34–E34. doi: 10.1208/pt010434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Li S, Liu S, Chien YW, Daggy BP, Mirchandani HL. Statistical optimization of gastric floating system for oral controlled delivery of calcium. AAPS PharmSciTech. 2001;2:E1–E1. doi: 10.1208/pt020101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Gavini E, Sanna V, Juliano C, Bonferoni MS, Giunchedi P. Mucoadhesive vaginal tablets as veterinary delivery system for the controlled release of an antimicrobial drug acriflavine. AAPS PharmSciTech. 2002;3:E20–E20. doi: 10.1208/pt030320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Shah D, Shah Y, Pradhan R. Development and evaluation of controlled release diltiazem hydrochloride microparticles using cross-linked poly(vinyl alcohol) Drug Dev Ind Pharm. 1997;23:567–574. [Google Scholar]
  • 12.Hosny EA, Al-Helw ARM, Al-Dardiri MA. Comparative study of invitro release and bioavailability of sustained release diclofenac sodium from certain hydrophilic polymers and commercial tablets in beagle dogs. Pharm Acta Helv. 1997;72:159–164. doi: 10.1016/S0031-6865(97)00010-1. [DOI] [PubMed] [Google Scholar]
  • 13.Nishihata T. Simple formulation of sustained release tablets of sodium diclofenac and examination in humans. Int J Pharm. 1987;40:125–128. doi: 10.1016/0378-5173(87)90057-3. [DOI] [Google Scholar]
  • 14.Rani M, Mishra B. Comparative evaluation of in-vitro performance of commercial and fabricated sustained release diclofenac sodium tablets. Ind J Pharm Sci. 2001;63:247–250. [Google Scholar]
  • 15.Rani M, Mishra B. Effect of admixed polymers on diclofenac sodium release from matrix tablets. Pharm Pharmacol Lett. 2001;11:76–78. [Google Scholar]
  • 16.Rani M, Mishra B. Development and evaluation of carbomer based matrices for the controlled delivery of diclofenac sodium. Acta Pharm Turc. 2003;41:5–10. [PubMed] [Google Scholar]
  • 17.Liu CH, Kao YH, Chen SC, Sokoloski TD, Sheu MT. In vitro and in vivo studies of the diclofenac sodium controlled-release matrix tablets. J Pharm Pharmacol. 1995;47:360–364. doi: 10.1111/j.2042-7158.1995.tb05811.x. [DOI] [PubMed] [Google Scholar]
  • 18.Traconis N, Rodriguez R, Campos ME, Villafuerte L. Influence of admixed polymers on the metronidazole release from hydroxypropyl methylcellulose matrix tablets. Pharm Acta Helv. 1997;72:131–138. doi: 10.1016/S0031-6865(97)00007-1. [DOI] [Google Scholar]
  • 19.Catellani PL, Colombo P, Peppas NA, Santi P, Bettini R. Partial permselective coating adds an osmotic contribution to drug release from swellable matrixes. J Pharm Sci. 1998;87:726–730. doi: 10.1021/js9800026. [DOI] [PubMed] [Google Scholar]
  • 20.Verma RK, Mishra B, Garg S. Osmotically controlled oral drug delivery. Drug Dev Ind Pharm. 2000;26:695–708. doi: 10.1081/DDC-100101287. [DOI] [PubMed] [Google Scholar]
  • 21.Bindschaedler C, Gurny R, Doelker E. Osmotically controlled drug delivery systems produced from organic solutions and aqueous dispersions of cellulose acetate. J Cont Rel. 1986;4:203–212. doi: 10.1016/0168-3659(86)90004-0. [DOI] [Google Scholar]
  • 22.Ramakrishna N, Mishra B. Plasticizer effect and comparative evaluation of cellulose acetate and ethylcellulose-HPMC combination coatings as semi-permeable membranes for oral osmotic pumps of naproxen sodium. Drug Dev Ind Pharm. 2002;28:403–412. doi: 10.1081/DDC-120003001. [DOI] [PubMed] [Google Scholar]
  • 23.United States Pharmacopoeia 24. United States Pharmacopoeial Convention, Rockville, MD: 2001;2051.
  • 24.Giagoudakis G, Markantonis SL. An alternative high-performance liquid-chromatographic method for the determination of diclofenac and flurbiprofen in plasma. J Pharm Biomed Anal. 1998;17:897–901. doi: 10.1016/S0731-7085(97)00258-6. [DOI] [PubMed] [Google Scholar]
  • 25.Sankar C, Rani M, Srivastava AK, Mishra B. Chitosan based pentazocine microspheres for intranasal systemic delivery: development and biopharmaceutical evaluation. Pharmazie. 2001;56:223–226. [PubMed] [Google Scholar]
  • 26.Reiss W, Sterlin H, Degen P, Faigle JW, Gerardin A, Moppert J, Sallman A, Schmin A, Schweizer A, Sule M, Thesbald W, Wagner J. Pharmacokinetics and metabolism of the anti-inflammatory agent voltaren. Scand J Rheumatol. 1978;22:17–29. doi: 10.3109/03009747809097212. [DOI] [PubMed] [Google Scholar]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES